 | In response to the final passage of H.R. 485, PIPC Chairman Tony Coelho is pleased to share this statement. |
Tony Coelho’s Statement Supporting the Protecting Health Care for All Patients Act, H.R. 4851/30/2024
Today, PIPC Chairman Tony Coelho issued the following statement of support for H.R. 485, The Protecting Health Care for All Patients Act.
PIPC Statement on Selection of Drugs under Medicare Drug Price Negotiation Program Guidance8/29/2023
The Partnership to Improve Patient Care (PIPC) has issued the following statement on the Centers for Medicare and Medicaid Services' (CMS) final guidance on the Medicare Drug Price Negotiation Program.
For Immediate Release
March 23, 2023 PIPC Chairman Tony Coelho issued the following statement on H.R. 485, the Protecting Health Care for All Patients Act.
The Protecting Health Care for All Patients Act represents an important step forward to strengthen and extend existing protections against use of the quality-adjusted life year (QALY) and similar metrics to all federal programs. The bill advances recent recommendations of the National Council on Disability and reflects longstanding, bipartisan concern with use of QALY standards in health care policy.
FOR IMMEDIATE RELEASE: November 17, 2021
On November 16, 2021, the Institute for Clinical and Economic Review (ICER) published its final evidence report for mavacamten, a new treatment for Hypertrophic Cardiomyopathy (HCM), a disease of the heart muscle affecting over 1 in 500 people.  In a report from the U.S. Department of Health and Human Services (HHS) to the White House laying out a “Comprehensive Plan for Addressing High Drug Prices,” HHS acknowledged the equity implications of certain methodologies, such as quality-adjusted-life-years (QALYs), for people of all ages with disabilities and chronic conditions and stated that drug pricing reforms should avoid utilization of methodologies that adversely impact access to needed medications for vulnerable populations.
 American Association of People with Disabilities This press release was first issued by the American Association of People with Disabilities (AAPD) on April 14, 2021.
Washington, D.C. – We are pleased to join the more than 90 organizations that signed a letter calling on policymakers to reject health policies that discriminate. Every life is valuable. We strongly urge policymakers to reject policies that discriminate against people with disabilities and chronic conditions, older adults, and reinforce health inequities.  PIPC is proud to have joined over 90 organizations in an open letter calling on policymakers to reject health policies that discriminate. Every life is valuable. We strongly urge policymakers to reject policies that discriminate against people with disabilities and chronic conditions, older adults, and reinforce health inequities
PIPC Statement on Behalf of People with Disabilities and Serious Chronic Conditions on MFN11/20/2020
Today, the Administration released an Interim Final Rule that would allow for the government to reference prescription drug prices established internationally, regardless of the metrics used by those countries or implications for access to care in those countries, for drugs covered under Part B of Medicare. The Partnership to Improve Patient Care and several other organizations expressed strong opposition to this concept when it was originally proposed in 2018.
As Chairman of the Partnership to Improve Patient Care (PIPC), I want to express my sincere congratulations to President-elect Joe Biden. Patients and people with disabilities are eager and excited to work with the President-elect and his team on policies that will improve their health and quality of life.
Today, the Administration released the text of an Executive Order allowing the Department of Health and Human Services (HHS) to rely on foreign governments to set prices for drugs covered under Medicare, regardless of the metrics used by those countries or implications for access to care for patients. The Partnership to Improve Patient Care (PIPC), along with other prominent patient and disability advocacy groups, has consistently expressed strong opposition to this concept, as it will have the impact of limiting and delaying access to needed treatments for Americans.
|
